SureTrader Advertisement Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

I don't know about the rest of you,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pphmtoolong Member Profile
Followed By 29
Posts 3,323
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences "GlobeNewswire Inc." - 11/23/2015 8:05:00 AM
Feature Analyst Alert and 4 Brief Updates "InvestorsHub NewsWire" - 11/10/2015 8:00:00 AM
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab’s Enhanced Anti-Tumor Activity When Combined Wi... "GlobeNewswire Inc." - 11/9/2015 8:05:00 AM
Peregrine Pharmaceuticals' Stock Sank in September: Is It Now a Buy? "The Motley Fool" - 10/17/2015 7:03:03 AM
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combin... "GlobeNewswire Inc." - 10/15/2015 8:05:00 AM
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2016 and Recent Developments "GlobeNewswire Inc." - 9/21/2015 8:46:28 PM
Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells "PR Newswire (US)" - 9/21/2015 8:50:00 AM
3 Key Takeaways From Peregrine Pharmaceuticals' Fourth-Quarter Results "The Motley Fool" - 7/15/2015 5:10:02 PM
Peregrine Pharmaceuticals Q4 Earnings Preview "The Motley Fool" - 7/10/2015 4:02:02 PM
Small Cap Stocks to Watch in Biotech "The Motley Fool" - 6/30/2015 12:02:03 PM
Undervalued and Underexposed NYSE-MKT Stock to be Profiled by Large Media Group and four brief reports "InvestorsHub NewsWire" - 6/15/2015 7:00:00 AM
1 Drug Will Make or Break These 3 Biotech Stocks "The Motley Fool" - 6/13/2015 7:18:02 AM
Special Profile & Four Companies Where Investors are Anticipating Success "InvestorsHub NewsWire" - 6/3/2015 7:00:00 AM
Peregrine Pharmaceuticals' Immuno-Oncology Agent Bavituximab to be Highlighted in Three Presentations at 2015 ASCO Annual Mee... "GlobeNewswire Inc." - 5/13/2015 5:00:00 PM
*Special Analyst Alert* and 4 Companies that are Worth a Look "InvestorsHub NewsWire" - 5/13/2015 7:00:00 AM
Preclinical Data Presented at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals' Phosphatidylserin... "GlobeNewswire Inc." - 4/21/2015 8:00:00 AM
Peregrine Pharmaceuticals Given a $5.00 Price Target at Roth Capital (PPHM) "Analyst Ratings Network" - 4/20/2015 3:24:37 PM
Data Presented at AACR Demonstrate Peregrine Pharmaceuticals' Bavituximab Induces Immune Activation in PD-L1 Negative NSCLC T... "GlobeNewswire Inc." - 4/20/2015 8:00:00 AM
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting "GlobeNewswire Inc." - 4/14/2015 8:00:00 AM
5 Promising Biotech Stocks Under $10 "The Motley Fool" - 4/3/2015 8:04:02 AM
Peregrine Pharmaceuticals Announces Promising Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine... "GlobeNewswire Inc." - 3/31/2015 12:45:22 PM
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2015 Financial Results and Recent Developments "GlobeNewswire Inc." - 3/12/2015 4:00:00 PM
Independent Research Initiates Analyst Coverage on Inventergy Global, Inc. (NASDAQ: INVT) with $1.20 Price Target "InvestorsHub NewsWire" - 3/12/2015 8:00:00 AM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 3/10/2015 4:00:00 PM
Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015 "GlobeNewswire Inc." - 3/5/2015 4:00:00 PM
pphmtoolong   Tuesday, 04/24/12 10:44:52 AM
Re: None
Post # of 243794 
I don't know about the rest of you, but I bought this stock based on Thorpe's approved patents and the early Bavi clinical studies.

It seems that Peregrine management and BOD have done everything reasonable to forward the Bavi agenda given the limited financial resources available. Running the trials overseas in Georgia and India could not have been easy, but they did it and got promising results. As in many other cases Bavi may not pan out in later stage trials. I don't blame management for trying with Bavi, and I don't blame management for the perversity of Mother Nature. I could blame them for excessive optimism, but the science seemed sound to them just as it seemed sound to us.

I don't like that managment has diluted the heck out of our stock, but I really don't buy any of the alternative financing plans I've seen presented here. I am a retired CPA; so I have some confidence assessment on this point.

If Bavi finally hits it out of the park with second line NSCLC, there is still a chance for us to make money. Otherwise, this has been a very expensive lesson in wishful thinking on biotechs. I blame only myself if Peregrine flops. I never should have thrown so much money into such a crap shoot.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist